Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Hamilton Point Investment Advisors LLC

Hamilton Point Investment Advisors LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.9% during the 3rd quarter, Holdings Channel reports. The fund owned 31,476 shares of the medical instruments supplier’s stock after purchasing an additional 279 shares during the period. Becton, Dickinson and Company makes up about 1.3% of Hamilton Point Investment Advisors LLC’s holdings, making the stock its 24th largest holding. Hamilton Point Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $7,589,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BDX. Acadian Asset Management LLC increased its stake in shares of Becton, Dickinson and Company by 843.7% in the 1st quarter. Acadian Asset Management LLC now owns 3,237 shares of the medical instruments supplier’s stock valued at $799,000 after purchasing an additional 2,894 shares in the last quarter. CreativeOne Wealth LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth $297,000. Advisors Asset Management Inc. lifted its holdings in Becton, Dickinson and Company by 3.9% during the first quarter. Advisors Asset Management Inc. now owns 3,850 shares of the medical instruments supplier’s stock valued at $953,000 after purchasing an additional 146 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Becton, Dickinson and Company by 15.6% in the first quarter. Canada Pension Plan Investment Board now owns 280,193 shares of the medical instruments supplier’s stock valued at $69,334,000 after purchasing an additional 37,851 shares during the period. Finally, Epoch Investment Partners Inc. increased its stake in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Epoch Investment Partners Inc. now owns 14,939 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 184 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BDX shares. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Down 0.6 %

NYSE BDX opened at $224.00 on Friday. The business’s fifty day simple moving average is $235.15 and its 200-day simple moving average is $234.56. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market cap of $64.74 billion, a PE ratio of 37.71, a P/E/G ratio of 1.68 and a beta of 0.43. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.42 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.86%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.